[go: up one dir, main page]

CL2018003473A1 - Nuevos derivados piperidinilo sustituidos con hetero(arilo), un proceso para su preparación y composiciones farmacéuticas que los contienen. - Google Patents

Nuevos derivados piperidinilo sustituidos con hetero(arilo), un proceso para su preparación y composiciones farmacéuticas que los contienen.

Info

Publication number
CL2018003473A1
CL2018003473A1 CL2018003473A CL2018003473A CL2018003473A1 CL 2018003473 A1 CL2018003473 A1 CL 2018003473A1 CL 2018003473 A CL2018003473 A CL 2018003473A CL 2018003473 A CL2018003473 A CL 2018003473A CL 2018003473 A1 CL2018003473 A1 CL 2018003473A1
Authority
CL
Chile
Prior art keywords
hetero
aryl
preparation
pharmaceutical compositions
compositions containing
Prior art date
Application number
CL2018003473A
Other languages
English (en)
Inventor
András Kotschy
Olivier Geneste
Maïa Chanrion
Didier Demarles
Csaba Wéber
Attila Vasas
Balázs Molnár
Árpád Kiss
Elodie Lewkowicz
Lisa Ivanschitz
James Brooke Murray
Alba Macias
Original Assignee
Servier Lab
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR1655387A external-priority patent/FR3052451B1/fr
Priority claimed from FR1663463A external-priority patent/FR3061177B1/fr
Application filed by Servier Lab, Vernalis R&D Ltd filed Critical Servier Lab
Publication of CL2018003473A1 publication Critical patent/CL2018003473A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPUESTOS DE FÓRMULA (I), EN LA QUE R1, R2, J, K, L, N Y W SON COMO SE HAN DEFINIDO EN LA DESCRIPCIÓN.
CL2018003473A 2016-06-10 2018-12-04 Nuevos derivados piperidinilo sustituidos con hetero(arilo), un proceso para su preparación y composiciones farmacéuticas que los contienen. CL2018003473A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1655387A FR3052451B1 (fr) 2016-06-10 2016-06-10 Nouveaux derives de piperidinyle hetero(aryl)-substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR1663463A FR3061177B1 (fr) 2016-12-28 2016-12-28 Nouveaux derives piperidinyles hetero(aryle)-substitues, procede pour leur preparation et compositions pharmaceutiques les contenant

Publications (1)

Publication Number Publication Date
CL2018003473A1 true CL2018003473A1 (es) 2019-05-10

Family

ID=59021522

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018003473A CL2018003473A1 (es) 2016-06-10 2018-12-04 Nuevos derivados piperidinilo sustituidos con hetero(arilo), un proceso para su preparación y composiciones farmacéuticas que los contienen.

Country Status (42)

Country Link
US (1) US10654849B2 (es)
EP (1) EP3468971B1 (es)
JP (1) JP6985299B2 (es)
KR (1) KR102003532B1 (es)
CN (1) CN109563094B (es)
AU (1) AU2017277732B2 (es)
BR (1) BR112018075284A2 (es)
CA (1) CA3027008C (es)
CL (1) CL2018003473A1 (es)
CO (1) CO2018013141A2 (es)
CR (1) CR20180563A (es)
CU (1) CU20180146A7 (es)
CY (1) CY1123069T1 (es)
DK (1) DK3468971T3 (es)
DO (1) DOP2018000264A (es)
EC (1) ECSP18090046A (es)
ES (1) ES2778700T3 (es)
GE (1) GEP20207161B (es)
HR (1) HRP20200556T1 (es)
HU (1) HUE048590T2 (es)
IL (1) IL263455B (es)
LT (1) LT3468971T (es)
MA (1) MA45223B1 (es)
MD (1) MD3468971T2 (es)
MX (1) MX374443B (es)
MY (1) MY196328A (es)
NI (1) NI201800133A (es)
PE (1) PE20220948A1 (es)
PH (1) PH12018502516B1 (es)
PL (1) PL3468971T3 (es)
PT (1) PT3468971T (es)
RS (1) RS60279B1 (es)
RU (1) RU2742271C2 (es)
SG (1) SG11201810576QA (es)
SI (1) SI3468971T1 (es)
SV (1) SV2018005792A (es)
TN (1) TN2018000395A1 (es)
TW (1) TWI647228B (es)
UA (1) UA123793C2 (es)
UY (1) UY37289A (es)
WO (1) WO2017212010A1 (es)
ZA (1) ZA201808286B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201807543YA (en) 2016-03-07 2018-09-27 Enanta Pharm Inc Hepatitis b antiviral agents
FR3052452B1 (fr) * 2016-06-10 2018-06-22 Les Laboratoires Servier Nouveaux derives de piperidinyle, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN110621316B (zh) 2017-04-21 2024-01-26 Epizyme股份有限公司 用ehmt2抑制剂进行的组合疗法
AU2018326474B2 (en) 2017-08-28 2024-07-25 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
GB201801562D0 (en) * 2018-01-31 2018-03-14 Almac Diagnostics Ltd Pharmaceutical compounds
UY38291A (es) * 2018-07-05 2020-06-30 Servier Lab Nuevos derivados de amino-pirimidonilo un proceso para su preparación y composiciones farmacéuticas
CN112955142A (zh) 2018-09-21 2021-06-11 英安塔制药有限公司 官能化杂环化合物作为抗病毒剂
UY38423A (es) * 2018-10-19 2021-02-26 Servier Lab Nuevos derivados amino-pirimidonil-piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
CN113271946A (zh) 2018-11-21 2021-08-17 英安塔制药有限公司 官能化杂环化合物作为抗病毒剂
US20220033397A1 (en) * 2018-12-06 2022-02-03 Almac Discovery Limited Pharmaceutical compounds and their use as inhibitors of ubiquitin specific protease 19 (usp19)
AU2020267757B2 (en) * 2019-05-06 2025-03-27 Valo Health, Inc. Inhibiting USP19
WO2020247444A1 (en) 2019-06-03 2020-12-10 Enanta Pharmaceuticals, Inc, Hepatitis b antiviral agents
US11760755B2 (en) 2019-06-04 2023-09-19 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US11472808B2 (en) 2019-06-04 2022-10-18 Enanta Pharmaceuticals, Inc. Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents
PT3994130T (pt) 2019-07-03 2024-10-07 Bayer Ag Tiofeno carboxamidas substituídas e derivados das mesmas como microbicidas
WO2021007488A1 (en) 2019-07-11 2021-01-14 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
WO2021055425A2 (en) 2019-09-17 2021-03-25 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
MX2022007665A (es) 2019-12-20 2022-07-19 Bayer Ag Tiofenocarboxamidas sustituidas y sus derivados.
CN113087718B (zh) * 2020-01-09 2024-02-09 四川科伦博泰生物医药股份有限公司 噻吩并嘧啶酮类化合物及其医药应用
GB202001980D0 (en) 2020-02-13 2020-04-01 Almac Discovery Ltd Therapeutic mentods
WO2021188414A1 (en) 2020-03-16 2021-09-23 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents
WO2023178035A1 (en) 2022-03-14 2023-09-21 Slap Pharmaceuticals Llc Multicyclic compounds
CN116574084A (zh) * 2023-04-17 2023-08-11 华南理工大学 一种噻吩衍生物及其合成方法与应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008108957A2 (en) * 2007-03-02 2008-09-12 Schering Corporation Piperidinyl-piperidine and piperazinyl-piperidine for use in the treatment of diabetes or pain
EP2565186A1 (en) * 2011-09-02 2013-03-06 Hybrigenics S.A. Selective and reversible inhibitors of ubiquitin specific protease 7
MA41291A (fr) 2014-12-30 2017-11-07 Forma Therapeutics Inc Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer
TWI770525B (zh) 2014-12-30 2022-07-11 美商瓦洛健康公司 作為泛素特異性蛋白酶7抑制劑之吡咯并及吡唑并嘧啶
HK1248220A1 (zh) 2015-02-05 2018-10-12 Forma Therapeutics, Inc. 喹唑啉酮和偶氮喹唑啉作为泛特丁胺蛋白酶7抑制剂
HK1248222A1 (zh) 2015-02-05 2018-10-12 Forma Therapeutics, Inc. 噻吩并嘧啶酮作为泛素特异性蛋白酶7抑制剂
JP2018504432A (ja) 2015-02-05 2018-02-15 フォーマ セラピューティクス,インコーポレイテッド ユビキチン特異的プロテアーゼ7阻害物質としてのイソチアゾロピリミジノン、ピラゾロピリミジノン及びピロロピリミジノン

Also Published As

Publication number Publication date
EP3468971B1 (en) 2020-02-19
HRP20200556T1 (hr) 2020-06-26
CY1123069T1 (el) 2021-10-29
UY37289A (es) 2018-01-02
SV2018005792A (es) 2019-05-20
SI3468971T1 (sl) 2020-07-31
MA45223B1 (fr) 2020-04-30
AU2017277732B2 (en) 2021-06-17
PH12018502516A1 (en) 2019-10-28
ECSP18090046A (es) 2019-01-31
SG11201810576QA (en) 2018-12-28
RU2018147424A (ru) 2020-07-13
BR112018075284A2 (pt) 2019-03-19
TW201802094A (zh) 2018-01-16
MY196328A (en) 2023-03-24
JP6985299B2 (ja) 2021-12-22
AU2017277732A1 (en) 2018-12-20
RU2742271C2 (ru) 2021-02-04
JP2019521115A (ja) 2019-07-25
ZA201808286B (en) 2021-07-28
CR20180563A (es) 2019-03-14
TN2018000395A1 (en) 2020-06-15
DK3468971T3 (da) 2020-05-18
IL263455A (en) 2019-01-31
EP3468971A1 (en) 2019-04-17
IL263455B (en) 2021-01-31
US20190144449A1 (en) 2019-05-16
CA3027008A1 (en) 2017-12-14
PH12018502516B1 (en) 2023-10-13
LT3468971T (lt) 2020-04-10
PL3468971T3 (pl) 2020-08-10
CU20180146A7 (es) 2019-07-04
MX374443B (es) 2025-03-06
ES2778700T3 (es) 2020-08-11
DOP2018000264A (es) 2019-05-15
CN109563094B (zh) 2022-03-18
NI201800133A (es) 2019-04-08
MX2018015212A (es) 2019-04-25
TWI647228B (zh) 2019-01-11
UA123793C2 (uk) 2021-06-02
PE20220948A1 (es) 2022-05-31
CN109563094A (zh) 2019-04-02
RU2018147424A3 (es) 2020-07-13
WO2017212010A1 (en) 2017-12-14
PT3468971T (pt) 2020-04-09
US10654849B2 (en) 2020-05-19
KR20190017032A (ko) 2019-02-19
MA45223A (fr) 2019-04-17
RS60279B1 (sr) 2020-06-30
GEP20207161B (en) 2020-10-12
CO2018013141A2 (es) 2018-12-14
CA3027008C (en) 2021-02-09
KR102003532B1 (ko) 2019-07-24
MD3468971T2 (ro) 2020-06-30
HUE048590T2 (hu) 2020-08-28

Similar Documents

Publication Publication Date Title
CL2018003473A1 (es) Nuevos derivados piperidinilo sustituidos con hetero(arilo), un proceso para su preparación y composiciones farmacéuticas que los contienen.
CL2018003474A1 (es) Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen.
NI201800076A (es) Nuevos derivados de amonio, un proceso para su preparación y composiciones farmacéuticas que los contienen
SV2017005590A (es) Nuevos derivados hidroxiacido un proceso para su preparacion y composiciones farmaceuticas que los contienen
SV2017005587A (es) Nuevos derivados hidroxiester, un proceso para su preparacion y composiciones farmaceutacas que los contienen
CL2017003205A1 (es) Nuevos derivados bicíclicos, un proceso para su preparación y composiciones farmacéuticas que los contienen.
CO7210068A1 (es) Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen
CL2017003163A1 (es) Nuevos derivados aminoácido, un proceso para su preparación y composiciones farmacéuticas que los contienen
DOP2018000082A (es) NUEVOS DERIVADOS DE PIRROLO[2,3-d]PIRIMIDINA, UN PROCESO PARA SU PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
DOP2018000083A (es) NUEVOS DERIVADOS DE IMIDAZO[4,5-b]PIRIDINA, UN PROCESO PARA SU PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
SV2014004879A (es) Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen